Beyond Air, Inc. Overview
Pro stress-test →Beyond Air is a medical device company focused on developing innovative technologies for treating pulmonary hypertension and other cardiopulmonary diseases. The company's lead product, LungFit PH, is a nitric oxide delivery system designed to improve blood flow in the lungs and reduce symptoms in patients with pulmonary hypertension.
Strategic Profile
Pro stress-test →Beyond Air positions itself as a clinical-stage biotech company developing non-invasive delivery solutions for inhaled nitric oxide therapy. The company leverages proprietary technology for targeted drug delivery to establish competitive differentiation in the rare disease and pulmonary hypertension markets.
Competitive Landscape
Pro stress-test →Beyond Air competes in the pulmonary hypertension treatment space against established pharmaceutical companies and other specialized biotech firms developing advanced delivery systems and novel therapeutics. Key competitors include Genentech/Roche (Tecfidera derivatives), Gilead Sciences (Letairis), and other companies in the PAH treatment market.
Industry Context
Beyond Air, Inc. operates in Medical Device / Specialty Pharmaceuticals - Pulmonary Hypertension.
Key facts
Founded: 2015 · Headquarters: Charlotte, NC